Business Wire

REMD Biotherapeutics Phase 2 Clinical Study of REMD-477 for Patients with Type 2 Diabetes Now Enrolling

CAMARILLO, Calif.--(BUSINESS WIRE)--REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing-based Cosci-REMD Biotherapeutics (“Cosci-REMD Bio”), today announced that its phase 2 ...
Business Wire

REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes

CAMARILLO, Calif.--(BUSINESS WIRE)--REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing CoSci-REMD Bio Med-Tech Co, Ltd (“Cosci-REMD Bio”), today announced they have ...
Yahoo Finance

REMD-477 (Volagidemab) for Type 1 Diabetes Mellitus: Emerging Drug Insight and Market Forecasts, 2019-2023 and 2023-2032 - Focus on 7 Major Markets

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "REMD-477 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...
PharmiWeb

REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes

CAMARILLO, Calif.--(BUSINESS WIRE)--REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing CoSci-REMD Bio Med-Tech Co, Ltd (“Cosci-REMD Bio”), today announced they have ...